Losartan Improves Heart Rate Variability and Heart Rate Turbulence in Heart Failure Due to Ischemic Cardiomyopathy

Journal of Cardiac Failure

Volumn 13, Issue 10, 2007, Pages 812-817

  Özdemir, Murat ^a   Arslan, Uǧur ^a   Türkoǧlu, Sedat ^a   Balcioǧlu, Serhat ^a   Çengel, Atiye ^a  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

losartan; Systolic heart failure

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; NITRIC ACID DERIVATIVE; SPIRONOLACTONE;

ADD ON THERAPY; ADULT; ARTICLE; CARDIOVASCULAR PARAMETERS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART FAILURE; HEART RATE TURBULENCE; HEART RATE VARIABILITY; HOLTER MONITORING; HUMAN; HYPERKALEMIA; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HEART RATE; HUMANS; LOSARTAN; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; TREATMENT OUTCOME;

EID: 36649034713     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2007.08.002     Document Type: Article

References (24)

1. Levine T.B., Francis G.S., Goldsmith S.R., Simon A., and Cohn J.N. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relationship to hemodynamic abnormalities in congestive heart failure. Am J Cardiol 49 (1982) 1659-1666
2. Camm A.J., Malik M., Bigger J.T., Breithardt G., Cerutti S., Cohen R.J., et al. Task Force of The European Society of Cardiology and The North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation, and clinical use. Eur Heart J 17 (1996) 354-381
3. Schmidt G., Malik M., Barthel P., Schneider R., Ulm K., Rolnitzky L., et al. Heart-rate turbulence after ventricular premature beats as a predictor of mortality after acute myocardial infarction. Lancet 353 (1999) 1390-1396
4. Barthel P., Schneider R., Bauer A., Ulm K., Schmitt C., Schomig A., et al. Risk stratification after acute myocardial infarction by heart rate turbulence. Circulation 108 (2003) 1221-1226
5. Koyama J., Watanabe J., Yamada A., Koseki Y., Konno Y., Toda S., et al. Evaluation of heart-rate turbulence as a new prognostic marker in patients with chronic heart failure. Circ J 66 (2002) 902-907
6. McMurray J.J.V., Ostergren J., Swedberg K., Granger C.B., Held P., Michelson E.L., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362 (2003) 767-771
7. Cohn J.N., and Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 (2001) 1667-1675
8. Ponikowski P., Anker S.D., Chua T.P., Szelemej R., Piepoli M., Adamopoulos S., et al. Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 79 (1997) 1645-1650
9. Szabo B., Veldhuisen D.J., Van der Veer N., Brouwer J., De Graeff P.A., and Crijns H.J. Prognostic value of heart rate variability in chronic congestive heart failure secondary to idiopathic or ischemic dilated cardiomyopathy. Am J Cardiol 79 (1997) 978-980
10. Nolan J., Batin P.D., Andrews R., Lindsay S.J., Brooksby P., Mullen M., et al. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom Heart Failure Evaluation and Assessment of Risk Trial (UK-Heart). Circulation 98 (1998) 1510-1516
11. Bullinga J.R., Alharethi R., Schram M.S., Bristow M.R., and Gilbert E.M. Changes in heart rate variability are correlated to hemodynamic improvement with chronic carvedilol therapy in heart failure. J Card Fail 11 (2005) 693-699
12. Goldsmith R.L., Bigger J.T., Bloomfield D.M., Krum H., Steinman R.C., Sackner-Bernstein J., et al. Long-term carvedilol therapy increases parasympathetic nervous system activity in chronic congestive heart failure. Am J Cardiol 80 (1997) 1101-1104
13. Binkley P.F., Haas G.J., Starling R.C., Nunziata E., Hatton P.A., Leier C.V., et al. Sustained augmentation of parasympathetic tone with angiotensin-converting enzyme inhibition in patients with congestive heart failure. J Am Coll Cardiol 21 (1993) 655-661
14. Flapan A.D., Nolan J., Neilson J.M., and Ewing D.J. Effect of captopril on cardiac parasympathetic activity in chronic cardiac failure secondary to coronary artery disease. Am J Cardiol 69 (1992) 532-535
15. Lin J.L., Chan H.L., Du C.C., Lin I.N., Lai C.W., Lin K.T., et al. Long-term beta blocker therapy improves autonomic nervous regulation in advanced congestive heart failure: a longitudinal heart rate variability study. Am Heart J 137 Pt 1 (1999) 658-665
16. Pousset F., Copie X., Lechat P., Jaillon P., Boissel J.P., Hetzel M., et al. Effects of bisoprolol on heart rate variabilty in heart failure. Am J Cardiol 77 (1996) 612-617
17. Pitt B., Segal R., Martinez F.A., Meurers G., Cowley A.J., Thomas I., et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349 (1997) 747-752
18. Pitt B., Poole-Wilson P.A., Segal R., Martinez F.A., Dickstein K., Camm A.J., et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 355 (2000) 1582-1587
19. Dickstein K., Kjekshus J., and and the OPTIMAAL Steering Committee for the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 360 (2002) 752-760
20. Pfeffer M.A., McMurray J.J.V., Velazquez E.J., Rouleau J.L., Koer L., Maggioni A.P., et al., for the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 (2003) 1893-1906
21. Solomon S.D., Wang D., Finn P., Skali H., Zornoff L., McMurray J.J.V., et al. Effect of candesartan on cause-specific mortality in heart failure patients. The Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. Circulation 110 (2004) 2180-2183
22. Tambara K., Fujita M., Sumita Y., Miyamoto S., Sekiguchi H., Eiho S., et al. Beneficial effect of candesartan treatment on cardiac autonomic nervous activity in patients with chronic heart failure: simultaneous recording of ambulatory electrocardiogram and posture. Clin Cardiol 27 (2004) 300-303
23. Petrie M.C., Padmanabhan N., McDonald J.E., Hillier C., Connell J.M., and McMurray J.J. Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. J Am Coll Cardiol 37 (2001) 1056-1061
24. Jorde U.P., Ennezat P.V., Lisker J., Suryadevara V., Infeld J., Cukon S., et al. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation 101 (2000) 844-846